Evidence map›Paper›PMID 42348656›Full record

Observational studyPloS one2026

Childhood to Adult Neurodevelopment in Gene-Expanded Huntington's Disease (ChANGE-HD): A prospective longitudinal neurodevelopmental study of Huntington's disease.

Mohit Neema, Nabil Halabi, Michael V Freedberg, Peggy C Nopoulos, ChANGE-HD investigators, coordinators, and consultants

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01951588, which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01951588 no registry record found
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Mohit NeemaDepartment of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City, Iowa, United States of America.ORCID https://orcid.org/0009-0003-5047-0166
Nabil HalabiDepartment of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City, Iowa, United States of America.
Michael V FreedbergDepartment of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City, Iowa, United States of America.ORCID https://orcid.org/0000-0003-3738-8259
Peggy C NopoulosDepartment of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City, Iowa, United States of America.
ChANGE-HD investigators, coordinators, and consultants

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although adult Huntington's disease (HD) studies have significantly advanced our understanding of the course of degeneration, they may underrepresent critical neurodevelopmental aspects of the disease. Significant gaps remain in understanding how mutant huntingtin affects early neurodevelopment, its long-term impact, as well as potential implications for treatment outcomes. The Childhood to Adult Neurodevelopment in Gene-Expanded Huntington's Disease (ChANGE-HD; NCT01951588) study aims to evaluate brain structure and function in premanifest, at-risk children and young adults, and explore HD's developmental origins. Here, we introduce the ChANGE-HD study, which will investigate and integrate the neurodevelopmental and neurodegenerative aspects of HD. The ChANGE-HD study is a prospective, seven-year multi-site observational study with an accelerated longitudinal design, where participants are not bound to a fixed schedule across multiple visits. Four hundred and fifty participants aged 6-30 years who are at risk for HD will be recruited and asked to return for multiple visits (if possible). At each visit, cognitive, motor, behavioral, blood/saliva, and MRI data are collected. Alongside ChANGE-HD, we are also recruiting individuals for the juvenile-onset HD (JOHD) study to investigate the neuropathology of this rarer form of HD. ChANGE-HD represents the first prospective multi-site study to systematically document brain structure and function during the premanifest phase of HD in children and young adults. Data collection is ongoing with first results anticipated in 2026-2027. The ChANGE-HD approach is likely to provide novel physiological insights and guide the development of therapeutic strategies tailored to both the developmental and degenerative phases of the disease.

Indexed as

Huntington DiseaseAdolescentAdultBrainChildFemaleHumansHuntingtin ProteinLongitudinal StudiesMagnetic Resonance ImagingMaleNeurodevelopmentProspective StudiesYoung AdultHuntingtin Protein

Identifiers

PMID42348656
PMCPMC13298748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.